Found: 6
Select item for more details and to access through your institution.
A phase I, dose-escalation study of PF-06650808, an anti-Notch3 antibody–drug conjugate, in patients with breast cancer and other advanced solid tumors.
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 1, p. 120, doi. 10.1007/s10637-019-00754-y
- By:
- Publication type:
- Article
A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 5, p. 836, doi. 10.1007/s10637-018-0560-6
- By:
- Publication type:
- Article
Multiplicity adjustments in testing for bioequivalence.
- Published in:
- Statistics in Medicine, 2015, v. 34, n. 2, p. 215, doi. 10.1002/sim.6247
- By:
- Publication type:
- Article
Inference of bioequivalence for log-normal distributed data with unspecified variances.
- Published in:
- Statistics in Medicine, 2014, v. 33, n. 17, p. 2924, doi. 10.1002/sim.6081
- By:
- Publication type:
- Article
A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis.
- Published in:
- Arthritis Research & Therapy, 2018, v. 20, n. 1, p. N.PAG, doi. 10.1186/s13075-018-1676-y
- By:
- Publication type:
- Article
A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy.
- Published in:
- Arthritis Research & Therapy, 2018, v. 20, n. 1, p. N.PAG, doi. 10.1186/s13075-018-1646-4
- By:
- Publication type:
- Article